nodes	percent_of_prediction	percent_of_DWPC	metapath
Goserelin—Glucose tolerance impaired—Furosemide—dilated cardiomyopathy	0.022	0.032	CcSEcCtD
Goserelin—LHCGR—Arf6 signaling events—AGTR1—dilated cardiomyopathy	0.0193	0.062	CbGpPWpGaD
Goserelin—LHCGR—Arf6 signaling events—ADRB2—dilated cardiomyopathy	0.0183	0.0588	CbGpPWpGaD
Goserelin—Incontinence—Furosemide—dilated cardiomyopathy	0.017	0.0246	CcSEcCtD
Goserelin—Breast enlargement—Spironolactone—dilated cardiomyopathy	0.0168	0.0244	CcSEcCtD
Goserelin—Infarction—Lisinopril—dilated cardiomyopathy	0.016	0.0233	CcSEcCtD
Goserelin—Blood cholesterol increased—Furosemide—dilated cardiomyopathy	0.0147	0.0214	CcSEcCtD
Goserelin—LHCGR—Peptide GPCRs—AGTR2—dilated cardiomyopathy	0.0138	0.0443	CbGpPWpGaD
Goserelin—LHCGR—Peptide GPCRs—CXCR3—dilated cardiomyopathy	0.0128	0.0411	CbGpPWpGaD
Goserelin—Breast pain—Spironolactone—dilated cardiomyopathy	0.0125	0.0181	CcSEcCtD
Goserelin—Amenorrhoea—Spironolactone—dilated cardiomyopathy	0.0124	0.018	CcSEcCtD
Goserelin—LHCGR—GPCRs, Class A Rhodopsin-like—MAS1—dilated cardiomyopathy	0.0121	0.0388	CbGpPWpGaD
Goserelin—Ulcer—Spironolactone—dilated cardiomyopathy	0.0115	0.0167	CcSEcCtD
Goserelin—LHCGR—Peptide GPCRs—AGTR1—dilated cardiomyopathy	0.0106	0.034	CbGpPWpGaD
Goserelin—Cramps of lower extremities—Spironolactone—dilated cardiomyopathy	0.01	0.0145	CcSEcCtD
Goserelin—Gynaecomastia—Spironolactone—dilated cardiomyopathy	0.00974	0.0142	CcSEcCtD
Goserelin—GNRHR—Peptide GPCRs—AGTR2—dilated cardiomyopathy	0.00924	0.0296	CbGpPWpGaD
Goserelin—Cerebral ischaemia—Lisinopril—dilated cardiomyopathy	0.0092	0.0134	CcSEcCtD
Goserelin—Transient ischaemic attack—Lisinopril—dilated cardiomyopathy	0.00881	0.0128	CcSEcCtD
Goserelin—GNRHR—Peptide GPCRs—CXCR3—dilated cardiomyopathy	0.00859	0.0275	CbGpPWpGaD
Goserelin—LHCGR—G alpha (s) signalling events—ADRB1—dilated cardiomyopathy	0.00822	0.0264	CbGpPWpGaD
Goserelin—Lethargy—Spironolactone—dilated cardiomyopathy	0.00806	0.0117	CcSEcCtD
Goserelin—Pelvic pain—Lisinopril—dilated cardiomyopathy	0.00731	0.0106	CcSEcCtD
Goserelin—GNRHR—GPCRs, Other—CXCR3—dilated cardiomyopathy	0.00728	0.0233	CbGpPWpGaD
Goserelin—GNRHR—Peptide GPCRs—AGTR1—dilated cardiomyopathy	0.00711	0.0228	CbGpPWpGaD
Goserelin—LHCGR—G alpha (s) signalling events—ADRB2—dilated cardiomyopathy	0.00666	0.0214	CbGpPWpGaD
Goserelin—LHCGR—Arf6 signaling events—EGFR—dilated cardiomyopathy	0.00647	0.0207	CbGpPWpGaD
Goserelin—Hyperuricaemia—Furosemide—dilated cardiomyopathy	0.00639	0.00928	CcSEcCtD
Goserelin—Gout—Furosemide—dilated cardiomyopathy	0.00634	0.00922	CcSEcCtD
Goserelin—Erectile dysfunction—Spironolactone—dilated cardiomyopathy	0.00629	0.00914	CcSEcCtD
Goserelin—Hyperlipidaemia—Lisinopril—dilated cardiomyopathy	0.00617	0.00896	CcSEcCtD
Goserelin—Drowsiness—Spironolactone—dilated cardiomyopathy	0.00609	0.00885	CcSEcCtD
Goserelin—Blood uric acid increased—Furosemide—dilated cardiomyopathy	0.00603	0.00877	CcSEcCtD
Goserelin—Renal failure—Spironolactone—dilated cardiomyopathy	0.00599	0.0087	CcSEcCtD
Goserelin—Herpes zoster—Lisinopril—dilated cardiomyopathy	0.0059	0.00858	CcSEcCtD
Goserelin—GNRHR—GPCRs, Other—ADRB2—dilated cardiomyopathy	0.00571	0.0183	CbGpPWpGaD
Goserelin—Cramps of lower extremities—Furosemide—dilated cardiomyopathy	0.00544	0.00791	CcSEcCtD
Goserelin—Endocrine disorder—Lisinopril—dilated cardiomyopathy	0.00536	0.00779	CcSEcCtD
Goserelin—Bladder pain—Furosemide—dilated cardiomyopathy	0.00536	0.00778	CcSEcCtD
Goserelin—Mental disability—Furosemide—dilated cardiomyopathy	0.00514	0.00747	CcSEcCtD
Goserelin—Breast pain—Lisinopril—dilated cardiomyopathy	0.00509	0.0074	CcSEcCtD
Goserelin—LHCGR—GPCRs, Class A Rhodopsin-like—AGTR2—dilated cardiomyopathy	0.00508	0.0163	CbGpPWpGaD
Goserelin—Thrombophlebitis—Furosemide—dilated cardiomyopathy	0.00497	0.00722	CcSEcCtD
Goserelin—Diabetes mellitus—Furosemide—dilated cardiomyopathy	0.00494	0.00718	CcSEcCtD
Goserelin—Arthropathy—Lisinopril—dilated cardiomyopathy	0.00489	0.0071	CcSEcCtD
Goserelin—Swelling—Furosemide—dilated cardiomyopathy	0.00487	0.00708	CcSEcCtD
Goserelin—Cough increased—Lisinopril—dilated cardiomyopathy	0.00485	0.00706	CcSEcCtD
Goserelin—Alopecia—Spironolactone—dilated cardiomyopathy	0.00483	0.00702	CcSEcCtD
Goserelin—Gout—Lisinopril—dilated cardiomyopathy	0.00476	0.00692	CcSEcCtD
Goserelin—LHCGR—GPCRs, Class A Rhodopsin-like—CXCR3—dilated cardiomyopathy	0.00473	0.0152	CbGpPWpGaD
Goserelin—LHCGR—GPCRs, Class A Rhodopsin-like—ADRB1—dilated cardiomyopathy	0.00458	0.0147	CbGpPWpGaD
Goserelin—Muscle spasms—Spironolactone—dilated cardiomyopathy	0.00458	0.00665	CcSEcCtD
Goserelin—Thirst—Furosemide—dilated cardiomyopathy	0.00452	0.00657	CcSEcCtD
Goserelin—Pulmonary embolism—Lisinopril—dilated cardiomyopathy	0.00444	0.00646	CcSEcCtD
Goserelin—Ill-defined disorder—Spironolactone—dilated cardiomyopathy	0.00442	0.00642	CcSEcCtD
Goserelin—Lethargy—Furosemide—dilated cardiomyopathy	0.00439	0.00638	CcSEcCtD
Goserelin—LHCGR—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.00435	0.014	CbGpPWpGaD
Goserelin—LHCGR—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.00435	0.014	CbGpPWpGaD
Goserelin—Cystitis noninfective—Lisinopril—dilated cardiomyopathy	0.00434	0.00631	CcSEcCtD
Goserelin—Malaise—Spironolactone—dilated cardiomyopathy	0.00429	0.00624	CcSEcCtD
Goserelin—Cystitis—Lisinopril—dilated cardiomyopathy	0.00429	0.00624	CcSEcCtD
Goserelin—Leukopenia—Spironolactone—dilated cardiomyopathy	0.00426	0.00619	CcSEcCtD
Goserelin—Urinary retention—Furosemide—dilated cardiomyopathy	0.00409	0.00594	CcSEcCtD
Goserelin—LHCGR—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.00405	0.013	CbGpPWpGaD
Goserelin—Bladder pain—Lisinopril—dilated cardiomyopathy	0.00402	0.00584	CcSEcCtD
Goserelin—Discomfort—Spironolactone—dilated cardiomyopathy	0.004	0.00582	CcSEcCtD
Goserelin—LHCGR—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.00392	0.0126	CbGpPWpGaD
Goserelin—Confusional state—Spironolactone—dilated cardiomyopathy	0.00392	0.00569	CcSEcCtD
Goserelin—LHCGR—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	0.00391	0.0125	CbGpPWpGaD
Goserelin—Hypertonia—Lisinopril—dilated cardiomyopathy	0.0039	0.00566	CcSEcCtD
Goserelin—Anaphylactic shock—Spironolactone—dilated cardiomyopathy	0.00388	0.00564	CcSEcCtD
Goserelin—Thrombocytopenia—Spironolactone—dilated cardiomyopathy	0.0038	0.00553	CcSEcCtD
Goserelin—Sleep disorder—Lisinopril—dilated cardiomyopathy	0.00373	0.00542	CcSEcCtD
Goserelin—Diabetes mellitus—Lisinopril—dilated cardiomyopathy	0.00371	0.00539	CcSEcCtD
Goserelin—LHCGR—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	0.00371	0.0119	CbGpPWpGaD
Goserelin—Hepatic function abnormal—Lisinopril—dilated cardiomyopathy	0.00369	0.00536	CcSEcCtD
Goserelin—Libido decreased—Lisinopril—dilated cardiomyopathy	0.00348	0.00506	CcSEcCtD
Goserelin—Somnolence—Spironolactone—dilated cardiomyopathy	0.00345	0.00502	CcSEcCtD
Goserelin—Pollakiuria—Furosemide—dilated cardiomyopathy	0.00343	0.00499	CcSEcCtD
Goserelin—Photosensitivity reaction—Furosemide—dilated cardiomyopathy	0.00339	0.00493	CcSEcCtD
Goserelin—Renal impairment—Lisinopril—dilated cardiomyopathy	0.00339	0.00493	CcSEcCtD
Goserelin—GNRHR—G alpha (q) signalling events—AGTR1—dilated cardiomyopathy	0.00338	0.0109	CbGpPWpGaD
Goserelin—Hyperglycaemia—Furosemide—dilated cardiomyopathy	0.00335	0.00487	CcSEcCtD
Goserelin—LHCGR—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	0.00335	0.0107	CbGpPWpGaD
Goserelin—LHCGR—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.00332	0.0106	CbGpPWpGaD
Goserelin—LHCGR—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.00332	0.0106	CbGpPWpGaD
Goserelin—Drowsiness—Furosemide—dilated cardiomyopathy	0.00331	0.00482	CcSEcCtD
Goserelin—Cerebrovascular accident—Lisinopril—dilated cardiomyopathy	0.00329	0.00478	CcSEcCtD
Goserelin—Renal failure—Furosemide—dilated cardiomyopathy	0.00326	0.00473	CcSEcCtD
Goserelin—Osteoarthritis—Lisinopril—dilated cardiomyopathy	0.00323	0.00469	CcSEcCtD
Goserelin—Feeling abnormal—Spironolactone—dilated cardiomyopathy	0.0032	0.00465	CcSEcCtD
Goserelin—Disturbance in sexual arousal—Lisinopril—dilated cardiomyopathy	0.0032	0.00465	CcSEcCtD
Goserelin—LHCGR—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.00318	0.0102	CbGpPWpGaD
Goserelin—Sweating—Furosemide—dilated cardiomyopathy	0.00318	0.00462	CcSEcCtD
Goserelin—Urticaria—Spironolactone—dilated cardiomyopathy	0.00309	0.00448	CcSEcCtD
Goserelin—LHCGR—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.00308	0.00988	CbGpPWpGaD
Goserelin—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.00307	0.00446	CcSEcCtD
Goserelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—AGTR1—dilated cardiomyopathy	0.00303	0.00971	CbGpPWpGaD
Goserelin—LHCGR—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.00299	0.00957	CbGpPWpGaD
Goserelin—Urinary tract disorder—Furosemide—dilated cardiomyopathy	0.00294	0.00427	CcSEcCtD
Goserelin—Urethral disorder—Furosemide—dilated cardiomyopathy	0.00292	0.00424	CcSEcCtD
Goserelin—Breast disorder—Lisinopril—dilated cardiomyopathy	0.00292	0.00424	CcSEcCtD
Goserelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.00292	0.00935	CbGpPWpGaD
Goserelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.00292	0.00935	CbGpPWpGaD
Goserelin—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.00286	0.00416	CcSEcCtD
Goserelin—Influenza—Lisinopril—dilated cardiomyopathy	0.00279	0.00405	CcSEcCtD
Goserelin—Eye disorder—Furosemide—dilated cardiomyopathy	0.00278	0.00404	CcSEcCtD
Goserelin—Pruritus—Spironolactone—dilated cardiomyopathy	0.00275	0.00399	CcSEcCtD
Goserelin—Angina pectoris—Lisinopril—dilated cardiomyopathy	0.00272	0.00395	CcSEcCtD
Goserelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.00271	0.00869	CbGpPWpGaD
Goserelin—Angiopathy—Furosemide—dilated cardiomyopathy	0.0027	0.00392	CcSEcCtD
Goserelin—Immune system disorder—Furosemide—dilated cardiomyopathy	0.00269	0.0039	CcSEcCtD
Goserelin—Bronchitis—Lisinopril—dilated cardiomyopathy	0.00268	0.0039	CcSEcCtD
Goserelin—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.00266	0.00386	CcSEcCtD
Goserelin—Arrhythmia—Furosemide—dilated cardiomyopathy	0.00266	0.00386	CcSEcCtD
Goserelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.00262	0.00842	CbGpPWpGaD
Goserelin—Dysuria—Lisinopril—dilated cardiomyopathy	0.00261	0.00379	CcSEcCtD
Goserelin—Upper respiratory tract infection—Lisinopril—dilated cardiomyopathy	0.00259	0.00377	CcSEcCtD
Goserelin—Erythema—Furosemide—dilated cardiomyopathy	0.00259	0.00376	CcSEcCtD
Goserelin—Malnutrition—Furosemide—dilated cardiomyopathy	0.00259	0.00376	CcSEcCtD
Goserelin—Dizziness—Spironolactone—dilated cardiomyopathy	0.00257	0.00373	CcSEcCtD
Goserelin—Erectile dysfunction—Lisinopril—dilated cardiomyopathy	0.00257	0.00373	CcSEcCtD
Goserelin—Flatulence—Furosemide—dilated cardiomyopathy	0.00255	0.00371	CcSEcCtD
Goserelin—LHCGR—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.00255	0.00818	CbGpPWpGaD
Goserelin—Photosensitivity reaction—Lisinopril—dilated cardiomyopathy	0.00255	0.0037	CcSEcCtD
Goserelin—Weight increased—Lisinopril—dilated cardiomyopathy	0.00254	0.00369	CcSEcCtD
Goserelin—Hyperglycaemia—Lisinopril—dilated cardiomyopathy	0.00252	0.00366	CcSEcCtD
Goserelin—Pneumonia—Lisinopril—dilated cardiomyopathy	0.0025	0.00363	CcSEcCtD
Goserelin—Muscle spasms—Furosemide—dilated cardiomyopathy	0.00249	0.00362	CcSEcCtD
Goserelin—Depression—Lisinopril—dilated cardiomyopathy	0.00248	0.0036	CcSEcCtD
Goserelin—Vomiting—Spironolactone—dilated cardiomyopathy	0.00247	0.00359	CcSEcCtD
Goserelin—Acute coronary syndrome—Lisinopril—dilated cardiomyopathy	0.00245	0.00356	CcSEcCtD
Goserelin—Rash—Spironolactone—dilated cardiomyopathy	0.00245	0.00356	CcSEcCtD
Goserelin—Dermatitis—Spironolactone—dilated cardiomyopathy	0.00245	0.00356	CcSEcCtD
Goserelin—Renal failure—Lisinopril—dilated cardiomyopathy	0.00244	0.00355	CcSEcCtD
Goserelin—Vision blurred—Furosemide—dilated cardiomyopathy	0.00244	0.00355	CcSEcCtD
Goserelin—Myocardial infarction—Lisinopril—dilated cardiomyopathy	0.00244	0.00354	CcSEcCtD
Goserelin—Headache—Spironolactone—dilated cardiomyopathy	0.00243	0.00354	CcSEcCtD
Goserelin—Jaundice—Lisinopril—dilated cardiomyopathy	0.00242	0.00352	CcSEcCtD
Goserelin—LHCGR—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.00242	0.00776	CbGpPWpGaD
Goserelin—Urinary tract infection—Lisinopril—dilated cardiomyopathy	0.00242	0.00351	CcSEcCtD
Goserelin—Anaemia—Furosemide—dilated cardiomyopathy	0.00239	0.00348	CcSEcCtD
Goserelin—Sweating—Lisinopril—dilated cardiomyopathy	0.00238	0.00346	CcSEcCtD
Goserelin—GNRHR—G alpha (q) signalling events—AGT—dilated cardiomyopathy	0.00238	0.00764	CbGpPWpGaD
Goserelin—Haematuria—Lisinopril—dilated cardiomyopathy	0.00237	0.00344	CcSEcCtD
Goserelin—LHCGR—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.00236	0.00756	CbGpPWpGaD
Goserelin—Epistaxis—Lisinopril—dilated cardiomyopathy	0.00234	0.00341	CcSEcCtD
Goserelin—Sinusitis—Lisinopril—dilated cardiomyopathy	0.00233	0.00339	CcSEcCtD
Goserelin—Leukopenia—Furosemide—dilated cardiomyopathy	0.00232	0.00337	CcSEcCtD
Goserelin—Nausea—Spironolactone—dilated cardiomyopathy	0.00231	0.00335	CcSEcCtD
Goserelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	0.00224	0.00719	CbGpPWpGaD
Goserelin—Rhinitis—Lisinopril—dilated cardiomyopathy	0.00224	0.00325	CcSEcCtD
Goserelin—Hepatitis—Lisinopril—dilated cardiomyopathy	0.00223	0.00324	CcSEcCtD
Goserelin—GNRHR—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.00222	0.00712	CbGpPWpGaD
Goserelin—GNRHR—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.00222	0.00712	CbGpPWpGaD
Goserelin—Pharyngitis—Lisinopril—dilated cardiomyopathy	0.00222	0.00322	CcSEcCtD
Goserelin—Urinary tract disorder—Lisinopril—dilated cardiomyopathy	0.0022	0.0032	CcSEcCtD
Goserelin—Oedema peripheral—Lisinopril—dilated cardiomyopathy	0.0022	0.0032	CcSEcCtD
Goserelin—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.00219	0.00318	CcSEcCtD
Goserelin—Urethral disorder—Lisinopril—dilated cardiomyopathy	0.00219	0.00318	CcSEcCtD
Goserelin—Dry mouth—Furosemide—dilated cardiomyopathy	0.00216	0.00313	CcSEcCtD
Goserelin—Confusional state—Furosemide—dilated cardiomyopathy	0.00213	0.0031	CcSEcCtD
Goserelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—dilated cardiomyopathy	0.00213	0.00683	CbGpPWpGaD
Goserelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.00213	0.00682	CbGpPWpGaD
Goserelin—Anaphylactic shock—Furosemide—dilated cardiomyopathy	0.00211	0.00307	CcSEcCtD
Goserelin—Shock—Furosemide—dilated cardiomyopathy	0.00208	0.00302	CcSEcCtD
Goserelin—Nervous system disorder—Furosemide—dilated cardiomyopathy	0.00207	0.00301	CcSEcCtD
Goserelin—Thrombocytopenia—Furosemide—dilated cardiomyopathy	0.00207	0.00301	CcSEcCtD
Goserelin—GNRHR—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.00206	0.00662	CbGpPWpGaD
Goserelin—Skin disorder—Furosemide—dilated cardiomyopathy	0.00205	0.00298	CcSEcCtD
Goserelin—Hyperhidrosis—Furosemide—dilated cardiomyopathy	0.00204	0.00297	CcSEcCtD
Goserelin—Angiopathy—Lisinopril—dilated cardiomyopathy	0.00202	0.00294	CcSEcCtD
Goserelin—Anorexia—Furosemide—dilated cardiomyopathy	0.00201	0.00293	CcSEcCtD
Goserelin—Chills—Lisinopril—dilated cardiomyopathy	0.002	0.00291	CcSEcCtD
Goserelin—GNRHR—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.002	0.00641	CbGpPWpGaD
Goserelin—Arrhythmia—Lisinopril—dilated cardiomyopathy	0.00199	0.0029	CcSEcCtD
Goserelin—Hypotension—Furosemide—dilated cardiomyopathy	0.00197	0.00287	CcSEcCtD
Goserelin—Alopecia—Lisinopril—dilated cardiomyopathy	0.00197	0.00287	CcSEcCtD
Goserelin—Mental disorder—Lisinopril—dilated cardiomyopathy	0.00196	0.00284	CcSEcCtD
Goserelin—Erythema—Lisinopril—dilated cardiomyopathy	0.00194	0.00282	CcSEcCtD
Goserelin—Malnutrition—Lisinopril—dilated cardiomyopathy	0.00194	0.00282	CcSEcCtD
Goserelin—Flatulence—Lisinopril—dilated cardiomyopathy	0.00191	0.00278	CcSEcCtD
Goserelin—Tension—Lisinopril—dilated cardiomyopathy	0.00191	0.00277	CcSEcCtD
Goserelin—Paraesthesia—Furosemide—dilated cardiomyopathy	0.0019	0.00276	CcSEcCtD
Goserelin—Nervousness—Lisinopril—dilated cardiomyopathy	0.00189	0.00274	CcSEcCtD
Goserelin—Back pain—Lisinopril—dilated cardiomyopathy	0.00188	0.00273	CcSEcCtD
Goserelin—Somnolence—Furosemide—dilated cardiomyopathy	0.00188	0.00273	CcSEcCtD
Goserelin—LHCGR—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.00187	0.00601	CbGpPWpGaD
Goserelin—LHCGR—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.00187	0.00601	CbGpPWpGaD
Goserelin—Muscle spasms—Lisinopril—dilated cardiomyopathy	0.00187	0.00271	CcSEcCtD
Goserelin—Decreased appetite—Furosemide—dilated cardiomyopathy	0.00184	0.00267	CcSEcCtD
Goserelin—Vision blurred—Lisinopril—dilated cardiomyopathy	0.00183	0.00266	CcSEcCtD
Goserelin—Fatigue—Furosemide—dilated cardiomyopathy	0.00182	0.00265	CcSEcCtD
Goserelin—Pain—Furosemide—dilated cardiomyopathy	0.00181	0.00263	CcSEcCtD
Goserelin—Constipation—Furosemide—dilated cardiomyopathy	0.00181	0.00263	CcSEcCtD
Goserelin—Ill-defined disorder—Lisinopril—dilated cardiomyopathy	0.0018	0.00262	CcSEcCtD
Goserelin—Anaemia—Lisinopril—dilated cardiomyopathy	0.0018	0.00261	CcSEcCtD
Goserelin—LHCGR—GPCR ligand binding—AGT—dilated cardiomyopathy	0.00179	0.00575	CbGpPWpGaD
Goserelin—Malaise—Lisinopril—dilated cardiomyopathy	0.00175	0.00255	CcSEcCtD
Goserelin—LHCGR—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.00174	0.00559	CbGpPWpGaD
Goserelin—Feeling abnormal—Furosemide—dilated cardiomyopathy	0.00174	0.00253	CcSEcCtD
Goserelin—Leukopenia—Lisinopril—dilated cardiomyopathy	0.00174	0.00253	CcSEcCtD
Goserelin—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.00173	0.00251	CcSEcCtD
Goserelin—Palpitations—Lisinopril—dilated cardiomyopathy	0.00172	0.0025	CcSEcCtD
Goserelin—GNRHR—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.00171	0.00547	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.0017	0.00546	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.0017	0.00546	CbGpPWpGaD
Goserelin—Cough—Lisinopril—dilated cardiomyopathy	0.0017	0.00246	CcSEcCtD
Goserelin—LHCGR—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.00169	0.00541	CbGpPWpGaD
Goserelin—Urticaria—Furosemide—dilated cardiomyopathy	0.00168	0.00244	CcSEcCtD
Goserelin—Abdominal pain—Furosemide—dilated cardiomyopathy	0.00167	0.00243	CcSEcCtD
Goserelin—Body temperature increased—Furosemide—dilated cardiomyopathy	0.00167	0.00243	CcSEcCtD
Goserelin—Arthralgia—Lisinopril—dilated cardiomyopathy	0.00165	0.0024	CcSEcCtD
Goserelin—Chest pain—Lisinopril—dilated cardiomyopathy	0.00165	0.0024	CcSEcCtD
Goserelin—Myalgia—Lisinopril—dilated cardiomyopathy	0.00165	0.0024	CcSEcCtD
Goserelin—Anxiety—Lisinopril—dilated cardiomyopathy	0.00165	0.0024	CcSEcCtD
Goserelin—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.00164	0.00239	CcSEcCtD
Goserelin—Discomfort—Lisinopril—dilated cardiomyopathy	0.00163	0.00237	CcSEcCtD
Goserelin—GNRHR—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.00162	0.00519	CbGpPWpGaD
Goserelin—Dry mouth—Lisinopril—dilated cardiomyopathy	0.00162	0.00235	CcSEcCtD
Goserelin—Confusional state—Lisinopril—dilated cardiomyopathy	0.0016	0.00232	CcSEcCtD
Goserelin—Oedema—Lisinopril—dilated cardiomyopathy	0.00159	0.0023	CcSEcCtD
Goserelin—Anaphylactic shock—Lisinopril—dilated cardiomyopathy	0.00159	0.0023	CcSEcCtD
Goserelin—LHCGR—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.00158	0.00507	CbGpPWpGaD
Goserelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.00158	0.00506	CbGpPWpGaD
Goserelin—Infection—Lisinopril—dilated cardiomyopathy	0.00158	0.00229	CcSEcCtD
Goserelin—Shock—Lisinopril—dilated cardiomyopathy	0.00156	0.00227	CcSEcCtD
Goserelin—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.00156	0.00226	CcSEcCtD
Goserelin—Thrombocytopenia—Lisinopril—dilated cardiomyopathy	0.00155	0.00226	CcSEcCtD
Goserelin—Tachycardia—Lisinopril—dilated cardiomyopathy	0.00155	0.00225	CcSEcCtD
Goserelin—Skin disorder—Lisinopril—dilated cardiomyopathy	0.00154	0.00224	CcSEcCtD
Goserelin—Hyperhidrosis—Lisinopril—dilated cardiomyopathy	0.00153	0.00223	CcSEcCtD
Goserelin—LHCGR—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.00153	0.00491	CbGpPWpGaD
Goserelin—Asthenia—Furosemide—dilated cardiomyopathy	0.00152	0.0022	CcSEcCtD
Goserelin—Anorexia—Lisinopril—dilated cardiomyopathy	0.00151	0.0022	CcSEcCtD
Goserelin—Pruritus—Furosemide—dilated cardiomyopathy	0.0015	0.00217	CcSEcCtD
Goserelin—Hypotension—Lisinopril—dilated cardiomyopathy	0.00148	0.00215	CcSEcCtD
Goserelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—dilated cardiomyopathy	0.00148	0.00474	CbGpPWpGaD
Goserelin—Diarrhoea—Furosemide—dilated cardiomyopathy	0.00145	0.0021	CcSEcCtD
Goserelin—Musculoskeletal discomfort—Lisinopril—dilated cardiomyopathy	0.00144	0.0021	CcSEcCtD
Goserelin—LHCGR—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	0.00144	0.00462	CbGpPWpGaD
Goserelin—Insomnia—Lisinopril—dilated cardiomyopathy	0.00143	0.00208	CcSEcCtD
Goserelin—Paraesthesia—Lisinopril—dilated cardiomyopathy	0.00142	0.00207	CcSEcCtD
Goserelin—Dyspnoea—Lisinopril—dilated cardiomyopathy	0.00141	0.00205	CcSEcCtD
Goserelin—Somnolence—Lisinopril—dilated cardiomyopathy	0.00141	0.00205	CcSEcCtD
Goserelin—Dizziness—Furosemide—dilated cardiomyopathy	0.0014	0.00203	CcSEcCtD
Goserelin—Dyspepsia—Lisinopril—dilated cardiomyopathy	0.0014	0.00203	CcSEcCtD
Goserelin—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.00138	0.002	CcSEcCtD
Goserelin—LHCGR—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	0.00137	0.00438	CbGpPWpGaD
Goserelin—Fatigue—Lisinopril—dilated cardiomyopathy	0.00137	0.00199	CcSEcCtD
Goserelin—Pain—Lisinopril—dilated cardiomyopathy	0.00136	0.00197	CcSEcCtD
Goserelin—Constipation—Lisinopril—dilated cardiomyopathy	0.00136	0.00197	CcSEcCtD
Goserelin—Vomiting—Furosemide—dilated cardiomyopathy	0.00134	0.00195	CcSEcCtD
Goserelin—Rash—Furosemide—dilated cardiomyopathy	0.00133	0.00194	CcSEcCtD
Goserelin—Dermatitis—Furosemide—dilated cardiomyopathy	0.00133	0.00193	CcSEcCtD
Goserelin—Headache—Furosemide—dilated cardiomyopathy	0.00132	0.00192	CcSEcCtD
Goserelin—LHCGR—Signaling by GPCR—AGTR1—dilated cardiomyopathy	0.00131	0.0042	CbGpPWpGaD
Goserelin—Feeling abnormal—Lisinopril—dilated cardiomyopathy	0.00131	0.0019	CcSEcCtD
Goserelin—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.0013	0.00188	CcSEcCtD
Goserelin—Urticaria—Lisinopril—dilated cardiomyopathy	0.00126	0.00183	CcSEcCtD
Goserelin—Nausea—Furosemide—dilated cardiomyopathy	0.00126	0.00182	CcSEcCtD
Goserelin—GNRHR—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.00125	0.00402	CbGpPWpGaD
Goserelin—GNRHR—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.00125	0.00402	CbGpPWpGaD
Goserelin—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.00125	0.00182	CcSEcCtD
Goserelin—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.00125	0.00182	CcSEcCtD
Goserelin—LHCGR—Signaling by GPCR—ADRB2—dilated cardiomyopathy	0.00124	0.00398	CbGpPWpGaD
Goserelin—GNRHR—GPCR ligand binding—AGT—dilated cardiomyopathy	0.0012	0.00385	CbGpPWpGaD
Goserelin—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.00117	0.0017	CcSEcCtD
Goserelin—GNRHR—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.00117	0.00374	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.00114	0.00365	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.00114	0.00365	CbGpPWpGaD
Goserelin—Asthenia—Lisinopril—dilated cardiomyopathy	0.00114	0.00165	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.00113	0.00363	CbGpPWpGaD
Goserelin—GNRHR—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.00113	0.00362	CbGpPWpGaD
Goserelin—Pruritus—Lisinopril—dilated cardiomyopathy	0.00112	0.00163	CcSEcCtD
Goserelin—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.00108	0.00158	CcSEcCtD
Goserelin—LHCGR—GPCR downstream signaling—RAC1—dilated cardiomyopathy	0.00106	0.0034	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.00106	0.0034	CbGpPWpGaD
Goserelin—Dizziness—Lisinopril—dilated cardiomyopathy	0.00105	0.00152	CcSEcCtD
Goserelin—GNRHR—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.00103	0.00329	CbGpPWpGaD
Goserelin—LHCGR—GPCR downstream signaling—AGT—dilated cardiomyopathy	0.00101	0.00325	CbGpPWpGaD
Goserelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—dilated cardiomyopathy	0.00101	0.00325	CbGpPWpGaD
Goserelin—Vomiting—Lisinopril—dilated cardiomyopathy	0.00101	0.00147	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.00101	0.00322	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.00101	0.00322	CbGpPWpGaD
Goserelin—Rash—Lisinopril—dilated cardiomyopathy	0.001	0.00145	CcSEcCtD
Goserelin—Dermatitis—Lisinopril—dilated cardiomyopathy	0.000999	0.00145	CcSEcCtD
Goserelin—Headache—Lisinopril—dilated cardiomyopathy	0.000993	0.00144	CcSEcCtD
Goserelin—GNRHR—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	0.000965	0.00309	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—RAC1—dilated cardiomyopathy	0.000964	0.00309	CbGpPWpGaD
Goserelin—Nausea—Lisinopril—dilated cardiomyopathy	0.000942	0.00137	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.000935	0.003	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—AGT—dilated cardiomyopathy	0.000921	0.00295	CbGpPWpGaD
Goserelin—GNRHR—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	0.000915	0.00293	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.000905	0.0029	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—AGTR1—dilated cardiomyopathy	0.000876	0.00281	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—ADRB2—dilated cardiomyopathy	0.000831	0.00266	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—AGTR1—dilated cardiomyopathy	0.000773	0.00248	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000758	0.00243	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—ADRB2—dilated cardiomyopathy	0.000733	0.00235	CbGpPWpGaD
Goserelin—GNRHR—GPCR downstream signaling—RAC1—dilated cardiomyopathy	0.000711	0.00228	CbGpPWpGaD
Goserelin—GNRHR—GPCR downstream signaling—AGT—dilated cardiomyopathy	0.000679	0.00218	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.000673	0.00216	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.000673	0.00216	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—RAC1—dilated cardiomyopathy	0.000645	0.00207	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—RAF1—dilated cardiomyopathy	0.000639	0.00205	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	0.00063	0.00202	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.000626	0.00201	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—AGT—dilated cardiomyopathy	0.000616	0.00198	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.000606	0.00194	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—RAC1—dilated cardiomyopathy	0.000569	0.00183	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—AGT—dilated cardiomyopathy	0.000544	0.00174	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—AGTR1—dilated cardiomyopathy	0.000518	0.00166	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—ADRB2—dilated cardiomyopathy	0.000491	0.00157	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—EGFR—dilated cardiomyopathy	0.000438	0.00141	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—RAF1—dilated cardiomyopathy	0.000428	0.00137	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	0.000422	0.00135	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—RAC1—dilated cardiomyopathy	0.000381	0.00122	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—RAF1—dilated cardiomyopathy	0.000378	0.00121	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—AGT—dilated cardiomyopathy	0.000364	0.00117	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—EGFR—dilated cardiomyopathy	0.000293	0.000941	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—EGFR—dilated cardiomyopathy	0.000259	0.00083	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—RAF1—dilated cardiomyopathy	0.000253	0.00081	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—EGFR—dilated cardiomyopathy	0.000173	0.000556	CbGpPWpGaD
